Matt Kaeberlein: Headlines vs the data

ByLongevity Notes Editorial
🟢
Peer-Reviewed Research
M
Matt Kaeberlein

Video Summary · March 31, 2026

View Full Protocol →

Key Takeaways

  • Be cautious when interpreting press releases: the Gallerie Grail trial headlines highlighted positive outcomes but failed its primary endpoint.
  • Always verify trial results beyond press releases, as they may focus on secondary outcomes rather than the main goal.
  • Monitor stock reactions to trial results as an indicator of market perception, e.g., Gallerie Grail’s stock dropped ~50% after the trial’s failure.

Bottom Line

Scrutinize trial results beyond headlines and press releases to assess their true effectiveness and reliability.

Explore More

Watch the Full Video

Medical Disclaimer

This article is for informational purposes only and does not constitute medical advice. The research summaries presented here are based on published studies and should not be used as a substitute for professional medical consultation. Always consult a qualified healthcare provider before making any changes to your health regimen.

⚡ Research Insider Weekly

Peer-reviewed health research, simplified. Early access findings, clinical trial alerts & regulatory news — delivered weekly.

No spam. Unsubscribe anytime. Powered by Beehiiv.

From Our Research Network

Part of the Evidence-Based Research Network

Similar Posts